UnitedHealth shares fall after HSBC downgrades rating, says shares not cheap enough

HSBC downgraded UnitedHealth (UNH) to 'reduce' with a price target of $270, citing risks to earnings growth and policy overhang despite the stock's 36% year-to-date decline and recent oversold bounce. Analyst Sidharth Sahoo pointed to higher medical costs, political pressure on drug prices, and potential Medicaid spending cuts as key reasons for the downgrade, suggesting the stock's discounted P/E ratio may not be an attractive entry point. UnitedHealth shares were down 6% premarket following the HSBC call.

Analysis

HSBC has issued a significant downgrade for UnitedHealth (UNH) shares, moving its rating to 'reduce' from 'hold' and substantially cutting the price target to $270 from $490, implying a potential 16% downside from the $321.58 pre-call closing price. This bearish outlook persists despite UNH's shares having already declined over 36% year-to-date in 2025 and trading at a forward price-earnings ratio of 13, near its decadal low. The downgrade, which prompted a 6% premarket drop in UNH shares, is attributed to several material risks to earnings, including the recent CEO departure, an ongoing Department of Justice investigation into fraud allegations, escalating medical costs, political pressure on drug pricing, and potential cuts to Medicaid spending. HSBC analyst Sidharth Sahoo contends that while some investors view the stock's 30% discount to its historical P/E as an attractive entry point, the fundamental outlook is expected to deteriorate further, overshadowing any short-term recovery, such as the 10% gain observed in the days leading up to the downgrade. While regaining investor confidence through its value-based care model is possible, further downward earnings revisions could negatively impact return on equity and valuation multiples.

Key Decisions for Investors

• Investors should exercise caution with UnitedHealth shares, as the HSBC downgrade highlights significant risks to earnings and the potential for further downside despite the stock's substantial year-to-date decline and historically low forward P/E ratio.
• Key factors to monitor include the progression and outcome of the Department of Justice investigation, the new CEO's strategic initiatives to address current headwinds, evolving medical cost trends, and any policy changes related to drug pricing or Medicaid funding.
• The recent share price appreciation prior to the downgrade may represent an oversold bounce rather than a fundamental recovery, and further deterioration in company fundamentals, as projected by HSBC, could lead to continued stock price pressure.